Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Schlechter on the Potential Future Implications of Botensilimab and Balstilimab in MSS mCRC

September 2nd 2025

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

FDA Grants Breakthrough Device Designation to Haystack MRD ctDNA Liquid Biopsy for Stage II CRC

August 31st 2025

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors

August 28th 2025

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Dr Lai on Post-Induction Treatment Strategies in mCRC

August 22nd 2025

Connie Lai, MD, discusses an analysis of post-induction maintenance vs treatment break in metastatic colorectal cancer.

Dr Marshall on the Role of Fruquintinib in the Treatment Paradigm for mCRC

August 20th 2025

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

Fruquintinib Efficacy Data Support Its Use in the Third-Line Advanced CRC Setting

August 20th 2025

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Magrolimab/Nivolumab Combos Drive Responses in Unresectable Advanced/Recurrent CRC

August 19th 2025

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

Dr García-Carbonero on Outcomes With Fruquintinib in mCRC Subgroups

August 15th 2025

Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.

Ongoing Research Prompts Key Sequencing Considerations in CRC, Pancreatic Cancer

August 11th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Fulzerasib Displays Efficacy and Tolerability in KRAS G12C–Mutated Metastatic CRC

August 11th 2025

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Dr Eng on the Future Role for Targeted Therapy in mCRC

August 7th 2025

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Botensilimab Plus Balstilimab Shows Durable Activity in Refractory CRC Across Lines of Therapy

August 7th 2025

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Rising Early‑Onset CRC Rates in Asia Underscore Global Trend in Incidence and Need for Coordinated Research Efforts

August 6th 2025

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

August 5th 2025

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC

August 5th 2025

Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.